April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Ocular Surface Changes in Patients Using Latanoprost and Travoprost With Sofzia
Author Affiliations & Notes
  • C. J. Cruz Colon
    Glaucoma,
    Wills Eye Institute, Philadelphia, Pennsylvania
  • J. Myers
    Glaucoma,
    Wills Eye Institute, Philadelphia, Pennsylvania
  • J. Katz
    Glaucoma,
    Wills Eye Institute, Philadelphia, Pennsylvania
  • T. Tai
    Glaucoma,
    Wills Eye Institute, Philadelphia, Pennsylvania
  • S. Wizov
    Glaucoma,
    Wills Eye Institute, Philadelphia, Pennsylvania
  • J. Wittpenn
    Glaucoma,
    Wills Eye Institute, Philadelphia, Pennsylvania
  • M. R. Moster
    Glaucoma,
    Wills Eye Institute, Philadelphia, Pennsylvania
  • M. Pro
    Glaucoma,
    Wills Eye Institute, Philadelphia, Pennsylvania
  • C. J. Rapuano
    Cornea,
    Wills Eye Institute, Philadelphia, Pennsylvania
  • Footnotes
    Commercial Relationships  C.J. Cruz Colon, None; J. Myers, Alcon, Merck, Pfizer, F; Alcon, Allergan, Pfizer, C; Alcon, Allergan, Pfizer, R; J. Katz, alcon, allergan, pfizer, F; glaukos, C; allergan, alcon, lumines, pfizer, R; T. Tai, None; S. Wizov, None; J. Wittpenn, allergan, C; Allergan, Bausch and Lomb, and Inspire, R; M.R. Moster, alcon, allergan, pfizer, merck,gentec, iop, F; allergan, alcon, pfizer, merck, gentec, iop, C; allergan, alcon,pfizer, merk,gentec, R; M. Pro, None; C.J. Rapuano, allergan, Inspire, Eyegate, C; Allergan, Alcon, Inspire, Baush & Lomb, Misticon, F.
  • Footnotes
    Support  Merk Grant
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 168. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. J. Cruz Colon, J. Myers, J. Katz, T. Tai, S. Wizov, J. Wittpenn, M. R. Moster, M. Pro, C. J. Rapuano; Ocular Surface Changes in Patients Using Latanoprost and Travoprost With Sofzia. Invest. Ophthalmol. Vis. Sci. 2010;51(13):168. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To compare ocular surface changes in patients using latanoprost and travoprost with sofzia.

Methods: : Patients were classified into 2 groups. Group 1 patients were naive to glaucoma therapy. Group 2 patients had been on latanoprost for at least one month in both eyes. In both groups, the patients were instructed to start (or continue) latanoprost in the right eye, and to start travoprost with sofzia in the left eye. At baseline, 1 month and 2 months tear break-up time (without anesthesia) was measured, conjunctival hyperemia was graded against a standard scale, subject drug preference was obtained, impression cytology with cellular typing was performed, lissamine green vital staining was graded, and intraocular pressure (IOP) by applanation tonometry was measured.

Results: : 2 month follow up for Group 1 (n=10): The eye receiving latanoprost therapy (OD) had statistically significantly less conjunctival staining than the eye receiving travoprost with sofzia (OS) therapy (3.40+/- 3.72 and 5.00+/- 4.45 p=0.029) and had less conjunctival hyperemia (3.30 +/- 2.95 and 4.50 +/- 3.21 p=0.029). There was no statistically significant difference in the change in tear break up time ( 0.710 +/- 6.71 vs 0.160 +/-6.38 p=0.669), change in IOP from baseline (-7.31+/- 7.29 vs -5.95 +/- 6.71 p=0.129), corneal staining (2.10+/- 3.00 vs 2.10 +/- 2.71 p=1.00), or impression cytology (0.457+/-0.348 vs 0.970+/-0.399).2 month follow up for Group 2 (n=8): The eye receiving latanoprost therapy (OD) had statistically significantly less corneal staining than the eye receiving travoprost with sofzia (OS) therapy (0.75+/-0.707 vs 1.50+/-0.756 p=0.048). There was no statistically significant difference in the change in tear break up time ( -1.24+/-4.61 vs -0.875 +/-4.60 p=0.761 ), conjunctival hyperemia (2.88 +/- 3.68 vs 4.00 +/- 5.01 p=0.122), change in IOP from baseline (0.188+/- 3.25 vs 0.0625 +/- 3.76 p=0.895), conjunctival staining (3.25+/- 3.92 vs 3.50+/- 3.46 p=0.598), or impression cytology ( 1.25+/-0.524 vs 0.957+/-0.394).In the last visit in Group 1, 30% preferred latanoprost, 20% preferred travoprost with sofzia and 50 % had no preference. In Group 2, 12.5% preferred latanoprost, 12.5% preferred travoprost with sofzia, and 75% had no preference.

Conclusions: : This small study has not yet demonstrated any clinically significant difference in the ocular surface effects of monotherapy with latanoprost or travoprost with sofzia in patients naïve to therapy or on prior latanoprost monotherapy.

Clinical Trial: : www.clinicaltrials.gov nct00798694

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • ocular irritancy/toxicity testing • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×